The management of anticoagulation in patients undergoing therapeutic plasma exchange: A concise review.

We surveyed multiple apheresis centers represented by the authors for their clinical approach to the management of anticoagulation issues during therapeutic plasma exchange (TPE). We present the results of their practices and a review of the pertinent literature. As plasma is removed during TPE, replacement with all or partial non-plasma-containing fluids (eg, 5% albumin) may lead to significant changes in hemostasis. These changes are amplified in patients who are receiving anticoagulation. We discuss various anticoagulants as well as the monitoring and adjustment of anticoagulation before, during, and after TPE. No single guideline can be applied, but rather, patients must be monitored individually, taking into account their often complex clinical conditions and medication profiles.

Use of standard laboratory methods to obviate routine dithiothreitol treatment of blood samples with daratumumab interference.

CONCLUSIONS: Daratumumab is an antibody currently used in the treatment of patients with refractory multiple myeloma. Blood samples from patients being treated with daratumumab may show panreactivity during pre-transfusion testing. To facilitate the provision of blood components for such patients, it is recommended that a baseline phenotype or genotype be established prior to starting treatment with daratumumab. If patient red blood cells (RBCs) require phenotyping after the start of daratumumab treatment, dithiothreitol (DTT) treatment of the patient's RBCs should be performed. The medical charts of four patients treated with daratumumab were reviewed. The individual number of doses ranged from 1 to 14; patient age ranged from 55 to 78 years; two men and two women were included in the review. Type and screen data were obtained from samples collected over 33 encounters with a range of 1 to 13 encounters per patient. All samples were tested initially by automated solid-phase testing. Any reactivity with solid phase led to tube testing with either low-ionic-strength saline, polyethylene glycol, or both. If incubation failed to eliminate the reactivity, the sample was sent to a reference laboratory for DTT treatment and phenotyping. Of the 33 samples tested, 23 (69.7%) samples had reactivity in solid-phase testing. In 8 of the 10 samples that did not react in solid-phase, testing was conducted more than four half-lives after the last dose of daratumumab. Of the 23 that had reactivity in solid-phase, 16 (69.6%) samples demonstrated loss of reactivity using common laboratory methods. For the seven patients whose sample reactivity was not initially eliminated, six were provided with phenotypically matched blood based on prior molecular testing. Only one sample was sent out for DTT treatment. These results suggest that daratumumab interference with pre-transfusion testing can be addressed using common laboratory methods. This finding could save time and money for laboratories that do not have DTT available.

Requirement for a Pathologist's Second Signature Limits Inappropriate Inpatient Thrombophilia Testing.

Thromboembolism is a condition that leads to the hospitalization of thousands of patients in the United States annually. Recent guidelines suggest that testing for hereditary, acquired and combined forms of thrombophilia be delayed following hospitalization for a first-time acute thrombotic event. Instead, thrombophilia testing would be performed in an outpatient setting, at least 1 month after discontinuation of anticoagulant therapy or 3 months after the thrombotic event, on the understanding that anticoagulation may affect some testing. Here, we provide our experience in instituting a system-wide policy change to limit thrombophilia testing in the inpatient setting. The policy change implemented led to a 90% reduction in number of tests ordered. We discuss the cost savings realized by limiting testing. These changes cost nothing to implement. Overall, limiting inpatient thrombophilia testing improves compliance with testing guidelines, provides better care for patients, and allows our institution to better utilize resources.

Therapeutic plasma exchange and pregnancy: A case report and guidelines for performing plasma exchange in a pregnant patient.

Therapeutic plasma exchange (TPE) has been demonstrated to be of significant clinical value in a number of diseases and conditions, with well-established guidelines and recommendations. However, technical support in providing this procedure for pregnant patients is largely absent from these recommendations, leaving therapeutic apheresis practitioners without guidance to safely and adequately treat appropriate conditions in this important patient population. Here, we describe our experience in treating a 35-year-old pregnant patient with relapsing-remitting multiple sclerosis with TPE. Additionally, we outline the principle considerations when developing her treatment plan, and we provide recommendations for apheresis practitioners when performing TPE in pregnant patients. J. Clin. Apheresis 32:191-195, 2017. © 2016 Wiley Periodicals, Inc.

Sebastian syndrome with abnormal platelet response to ristocetin.

BACKGROUND: Sebastian syndrome is characterized by enlarged platelets and Döhle-like body leukocyte inclusions. This syndrome is an MYH-9-related disease, a group that also includes May-Hegglin anomaly and Fechtner syndrome. The differential diagnosis of the MYH-9 diseases requires ultrastructural studies. Certain in vitro aggregation responses may be abnormal in these conditions. OBSERVATIONS: A 6-month-old boy presented with macrothrombocytopenia but no overt bleeding tendency. Giant platelets and Döhle-like body leukocyte inclusions were present in blood smears from both the patient and his mother. Electron microscopy confirmed ultrastructural features consistent with Sebastian syndrome. Platelet aggregation studies were normal except for an impaired response to the agonist ristocetin. CONCLUSIONS: In this patient peripheral blood analyses and platelet aggregation studies revealed disease features shared with the Bernard-Soulier syndrome, but this syndrome was excluded by cellsurface glycoprotein analysis.

Ethnic differences in expectations for aging among older adults.

Age-expectations of 611 non-Latino white, African-American, and Latino seniors recruited at 14 community-based senior centers in the greater Los Angeles region were compared. Participants completed the Expectations Regarding Aging (ERA-38) Survey, a self-administered instrument with previously demonstrated reliability and validity for measuring age-expectations. Analysis of variance was used to compare unadjusted differences between scores across ethnic groups. To examine whether observed differences persisted after adjusting for health and sociodemographic characteristics, a series of linear regression models was constructed, with the dependent variable being total ERA-38 score and the primary independent variables being African-American and Latino ethnicity (reference group=white), adjusting for age, sex, physical and mental health-related quality of life (HRQoL), medical comorbidity, activity of daily living (ADL) impairments, depression, and education. Latinos had significantly lower overall age-expectations than non-Latino whites or African Americans after adjusting for age and sex (parameter estimate=-3.4, P=.01); this difference persisted after adjusting for health variables including medical comorbidity, HRQoL, ADL impairments, and depression. After adjusting for education, being Latino was no longer significantly associated with lower age-expectations (parameter estimate=-1.9, P=.18). Being African American was not significantly associated with age-expectations in any of the adjusted models. Younger age and better HRQoL were associated with higher age-expectations in all models. In conclusion, of these 611 older adults recruited at senior centers in the greater Los Angeles region, Latinos had significantly lower age-expectations than non-Latino whites and African Americans, even after adjusting for health characteristics, but differences in educational levels explained this difference.

Pilot of a hospice-based elective to learn comfort with dying patients in undergraduate medical education.

BACKGROUND: A majority of medical students feel uncomfortable with dying patients. OBJECTIVE: We designed a pilot program to train medical students to be hospice volunteers to determine (1) the value of contact with dying patients in changing medical students' comfort level and (2) the mechanics of starting such a course in cooperation with a nonacademic agency. DESIGN: Students were required to undergo hospice training provided by the local hospice. Students were eligible for Hospice volunteer placement after the training was completed. This provided students with an opportunity to interact with dying patients in a nonclinical capacity. Quantitative data and qualitative data were collected about the students' experiences with patients as well as about the effectiveness of the rotation. SETTING/SUBJECTS: First- through fourth-year medical students were recruited to participate in this semester long project via a medical school-wide e-mail. MEASUREMENTS: (1) A self-rating questionnaire on emotions and attitudes about death and dying at three points in time: before training, after training, and after placement; (2) A Likert-type questionnaire on barriers to participation and the usefulness of the components of an end-of-life course; (3) The "Attitudes About End-of-Life Scale"; (4) An in-depth structured interview with students after completion of the course. RESULTS: Fourteen students participated in the evaluation phase of the program and reported increased comfort in interacting with dying patients after participating in the program. Students had less anxiety and fear of being around a dying person after placement as compared to before training. In-depth student interviews provided valuable qualitative data on the impact of the pilot, and insight into the strengths and areas for improvement in this type of elective. CONCLUSIONS: A Hospice based elective can be an effective model for facilitating learning about how to approach the patient with a terminal illness.